Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

-Presbyopia in each eye that impacts daily activities.

Exclusion Criteria:

• Use of any topical ophthalmic medications, including artificial tears

• Contact lens use in either eye within 14 days or planned use during the study

• History of eye surgery

• Diagnosis of any type of glaucoma or ocular hypertension